[A report on Ocusert (author's transl)].
The third communication on the drug delivery system Ocusert (Alza Corporation, Palo Alto; Federal Republic of Germany: Chemic Grümenthal) deals with experiences of a 15 month follow-up study. Again we found that the system provides effective around-the-clock control for at least 7 days. During 15 months the system was effective in all patients. In comparison to pilocarpine-eyedrops the Ocusert-system has the following advantages: less pilocarpine-induced myopia and miosis, myopia and miosis extremely constant, minimal local side effects, reduced amount of drug release, almost no therapeutic discomfort for the patient, isolating the patient from the disease and good controlpossibility of the success of the treatment. The problems of a permanent drug release are discussed.
D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D005260:Female; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D010862:Pilocarpine / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013997:Time Factors
D003692:Delayed-Action Preparations; D010862:Pilocarpine
Ocusert, ein neuartiges Medikamententrägersystem für die Glaukombehandlung